Dr Lawrence R Jones, MD | |
901 Leighton Ave, Suite 501, Anniston, AL 36207-5700 | |
(256) 237-6755 | |
(256) 236-1823 |
Full Name | Dr Lawrence R Jones |
---|---|
Gender | Male |
Speciality | Obstetrics/gynecology |
Experience | 47 Years |
Location | 901 Leighton Ave, Anniston, Alabama |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194828715 | NPI | - | NPPES |
51540716 | Other | AL | BLUE CROSS OF ALABAMA |
009942861 | Medicaid | AL | |
051540716 | Other | AL | MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 13865 (Nebraska) | Secondary |
207V00000X | Obstetrics & Gynecology | 23568 (Alabama) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Anniston Obgyn Associates, P.c. | 1658322169 | 4 |
News Archive
Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of once-a-day Tiazac® extended release capsules.
Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch of the PARADYM RF family of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices.
Shire plc and Parion Sciences, Inc. have announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.
The polarized debate over the use of organic and inorganic practices to boost farm yields is slowing action and widespread farmer adoption of approaches that could radically transform Africa's food security situation, according to a group of leading international scientists meeting in Kigali this week.
› Verified 5 days ago
Entity Name | Anniston Obgyn Associates, P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1760447510 PECOS PAC ID: 1658322169 Enrollment ID: O20050202000245 |
News Archive
Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of once-a-day Tiazac® extended release capsules.
Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch of the PARADYM RF family of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices.
Shire plc and Parion Sciences, Inc. have announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.
The polarized debate over the use of organic and inorganic practices to boost farm yields is slowing action and widespread farmer adoption of approaches that could radically transform Africa's food security situation, according to a group of leading international scientists meeting in Kigali this week.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Lawrence R Jones, MD 901 Leighton Ave, Suite 501, Anniston, AL 36207-5700 Ph: (256) 237-6755 | Dr Lawrence R Jones, MD 901 Leighton Ave, Suite 501, Anniston, AL 36207-5700 Ph: (256) 237-6755 |
News Archive
Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of once-a-day Tiazac® extended release capsules.
Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch of the PARADYM RF family of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices.
Shire plc and Parion Sciences, Inc. have announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.
The polarized debate over the use of organic and inorganic practices to boost farm yields is slowing action and widespread farmer adoption of approaches that could radically transform Africa's food security situation, according to a group of leading international scientists meeting in Kigali this week.
› Verified 5 days ago
Mr. Larry Braden Richmond Jr., MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 731 Leighton Ave, Suite 401, Anniston, AL 36207 Phone: 256-435-2229 Fax: 256-782-2904 | |
Jeffrey W Collins, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 901 Leighton Ave Ste 102, Anniston, AL 36207 Phone: 256-294-7010 Fax: 256-405-1138 | |
Jacquline A Tessen, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1010 Christine Ave, Anniston, AL 36207 Phone: 256-236-5631 Fax: 256-624-9388 | |
Ms. Barbara Louise Moersch, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 825 Keith Ave, Anniston, AL 36207 Phone: 256-238-0448 Fax: 256-238-1685 | |
Dr. James W. Mullis Jr., MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 721 E 10th St, Anniston, AL 36207 Phone: 256-237-2610 Fax: 256-236-5275 | |
Joshua Johannson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 171 Town Center Dr, Anniston, AL 36205 Phone: 256-241-0885 |